- Home
- SDHC vs OBIO Comparison
SDHC vs OBIO Comparison
Compare SDHC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDHC | OBIO |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.7M | 172.1M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | SDHC | OBIO |
|---|---|---|
| Price | $19.99 | $4.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $16.70 | $13.67 |
| AVG Volume (30 Days) | 80.5K | ★ 332.9K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $998,173,000.00 | $2,818,000.00 |
| Revenue This Year | $0.47 | $36.43 |
| Revenue Next Year | $7.65 | $2.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.26 | 6.46 |
| 52 Week Low | $15.00 | $2.20 |
| 52 Week High | $33.72 | $6.30 |
Technical Indicators
Market Signals| Indicator | SDHC | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 46.26 |
| Support Level | $20.31 | $4.15 |
| Resistance Level | $21.19 | $5.42 |
| Average True Range (ATR) | 1.05 | 0.37 |
| MACD | 0.23 | -0.11 |
| Stochastic Oscillator | 68.56 | 3.92 |
Price Performance
Historical ComparisonAbout SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.